Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8NAC3
UPID:
I17RC_HUMAN
Alternative names:
Interleukin-17 receptor homolog; Interleukin-17 receptor-like protein; ZcytoR14
Alternative UPACC:
Q8NAC3; A8BWC1; A8BWC9; A8BWD5; E9PHG1; E9PHJ6; Q6UVY3; Q6UWD4; Q8NFS1; Q9BR97
Background:
Interleukin-17 receptor C (IL-17RC), also known as Interleukin-17 receptor homolog, plays a pivotal role in the immune system. It acts as a receptor for IL17A and IL17F, cytokines crucial for antimicrobial defense and tissue integrity. IL-17RC's involvement in signaling pathways like NF-kappa-B and MAPkinase underscores its importance in immune responses, particularly in neutrophil activation and recruitment.
Therapeutic significance:
IL-17RC's association with familial Candidiasis, a condition marked by impaired immune responses to fungal infections, highlights its therapeutic potential. Targeting IL-17RC could lead to innovative treatments for immune disorders and enhance our ability to combat fungal infections.